Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pulmonary/Respiratory Diseases | Otolaryngology | Immunology/Infectious Diseases
Disease Category: Allergies & Asthma

Trial Information

A 28 day study evaluating the safety of ragweed (ambrosia artemisiifolia) soblingual tablet in adult subjects 50 years old or older with ragweed induced rhinoconjunctivitis.

This research study is to evaluate the safety of ragweed (ambrosia artemisiifolia) sublingual tablet in adult subjects with or without asthma and ragweed induced allergy.

Patient Inclusion Critieria:

• 50 or older
• Ragweed allergy of 2 years or more
• Positive skin test

Patient Exclusion Criteria:

• Asthma that requires ICS or maintenance
• Use of anti-allergy medications during study
• History of chronic urticaria or angioedema
• Anaphylaxis with cardiorespiratory symptoms
• Current severe atopic dermatitis

Nancy Canada, CCRC
Allergy Asthma Research Institute
333 Londonderry Drive, Suite #110
Waco, TX 76712
Phone: 254-751-1144, ext 351

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.